Conditions: Schizophrenia Bipolar Disorder
Keywords: Open Label Aripiprazole Bipolar I Disorder, Manic or Mixed Episode
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 325
Healthy volunteers: no

Brief summary:
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.

Detailed description:

Arms:
arm 1: All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).

Interventions: intervention 1: Aripiprazole
Intervention descriptions: intervention 1: 2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses

Protocol document: